SPR720-202; PoC MAC Study
A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose-Ranging Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared with Placebo for the Treatment of Patients with Mycobacterium avium Complex (MAC) Pulmonary Disease
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II
- Conditions Being Studied: Mycobacterium Avium Complex (MAC) Pulmonary Disease
Study Purpose
To evaluate the microbiological response and clinical efficacy of SPR720 compared with placebo in patients with non- tuberculous mycobacterial pulmonary disease (NTM-PD). • To evaluate the safety and tolerability of SPR720 in a patient population with NTM-PD. • To evaluate the pharmacokinetics (PK) of SPR719, active moiety, following orally (PO) administered prodrug SPR720 in a patient population with NTM-PD.
Who Can Participate
Age: 18 and older
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00002141
- StudyID: 2023-01370
- ClinicalTrials.gov: NCT05496374
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422